ASCO/EHA/ICML 2021 – Matthew Davids
Matthew Davids depicts the most interesting trial results in the field of CLL treatment at the EHA 2021 congress, gives an outlook on the most promising agents currently tested for use not only in elderly but also in young, fit CLL patients and talks about combinations that might be implemented as pillars of CLL treatment based on current trials.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA B-cell rec
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma Patients w
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malignancies
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malign
Waldenström’s macroglobulinemia: outcome optimization via combinations
Waldenström’s macroglobulinemia: outcome optimization via combinations Final an
CLL/SLL: current perspectives across a range of potent agents
CLL/SLL: current perspectives across a range of potent agents ALPINE: zanubruti
